EP Patent

EP0893997A1 — Paroxetine in treatment of depression

Assigned to SmithKline Beecham Ltd · Expires 1999-02-03 · 27y expired

What this patent protects

Paroxetine or a pharmaceutically acceptable salt thereof is used for treating and/or preventing the following depression sub-types: adolescent, bipolar, elderly, major, minor, moderate, recurrent, refractory, severe unipolar, dysthymia, post natal, double depression, post psychot…

USPTO Abstract

Paroxetine or a pharmaceutically acceptable salt thereof is used for treating and/or preventing the following depression sub-types: adolescent, bipolar, elderly, major, minor, moderate, recurrent, refractory, severe unipolar, dysthymia, post natal, double depression, post psychotic, post viral, bereavement, primary, secondary, post traumatic stress disorder and depression associated with withdrawal from substances of abuse such as alcohol, nicotine, cocaine, heroin, benzodiazepines, in human or non-human animals. A preferred salt of paroxetine is the hydrochloride, particularly in crystalline form, such as the hemi-hydrate.

Drugs covered by this patent

Patent Metadata

Patent number
EP0893997A1
Jurisdiction
EP
Classification
Expires
1999-02-03
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.